Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Pushes Ahead With Aduhelm Confirmatory Trial As CMS Final Decision Looms

Executive Summary

Biogen interim head of R&D Priya Singhal talked to the Pink Sheet about ramping up the Phase IV trial for Aduhelm, the CMS coverage determination and taking over R&D at a challenging time for the company.

You may also be interested in...



Biogen's Aduhelm Defense Highlights Therapeutic Area Discrepancies

The company's comments to CMS on the proposed NCD for amyloid-targeting therapies for Alzheimer's disease says the differences between Alzheimer's and other areas could represent a legal issue.

Medicare Coverage Policy For Alzheimer's Drugs ‘Negates’ Value Of Accelerated Approval, Lilly Says

Lilly downplays expectations for an US FDA accelerated approval of donanemab, given expectations that Medicare will persist in its plan to withhold coverage for Alzheimer's drugs outside of clinical trials. Policy experts are divided on whether the decision sets a precedent for future accelerated approvals.

Lilly Waiting On Phase III Data For Donanemab

Lilly no longer plans to complete an accelerated approval submission for Alzheimer’s candidate donanemab during Q1 following the CMS draft coverage decision for amyloid-targeting therapies.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel